The biocompatibility of rapidly degrading polymeric stents in porcine carotid arteries

Biomaterials

Volumn 31, Issue 31, 2010, Pages 7847-7855

  Zamiri, P ^a   Kuang, Y ^a   Sharma, U ^a   Ng, T F ^a   Busold, R H ^a   Rago, A P ^a   Core, L A ^a   Palasis, M ^a  

^a Arsenal Medical   (United States)

Author keywords

Bioabsorbable polymers; Biocompatibility; L PLA; PDO; PLGA; Stent

Indexed keywords

BIOABSORBABLE POLYMER; L-PLA; PDO; PLGA; STENT;

ABSORPTION; BIOCOMPATIBILITY; LACTIC ACID; MATERIALS TESTING; ORGANIC ACIDS; ORGANIC POLYMERS;

POLYMERS;

GLYCOLIC ACID; POLYDIOXANONE; POLYLACTIC GLYCOLIC ACID; POLYMER; UNCLASSIFIED DRUG;

ANGIOGRAPHY; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BALLOON; BARE METAL STENT; BIOCOMPATIBILITY; CAROTID ARTERY; CAROTID ARTERY INJURY; CONTROLLED STUDY; HISTOPATHOLOGY; IN VIVO STUDY; INFLAMMATION; INTIMA; MATERIALS TESTING; MORPHOMETRICS; NONHUMAN; PATENT; POLYMERIZATION; PRIORITY JOURNAL;

ANGIOGRAPHY; ANIMALS; BIOCOMPATIBLE MATERIALS; BIOMECHANICS; CAROTID ARTERIES; INFLAMMATION; LACTIC ACID; MATERIALS TESTING; POLYGLYCOLIC ACID; STENTS; TRANSITION TEMPERATURE; VASCULAR PATENCY;

SUS;

EID: 77956009636     PISSN: 01429612     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biomaterials.2010.06.057     Document Type: Article

References (54)

1. Auer J., Leitner A., Berent R., Lamm G., Lassnig E., Krennmair G. Long-term outcomes following coronary drug-eluting- and bare-metal-stent implantation. Atherosclerosis 2009.
2. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 2004, 364(9434):583-591.
3. Hofma S.H., Whelan D.M., van Beusekom H.M., Verdouw P.D., van der Giessen W.J. Increasing arterial wall injury after long-term implantation of two types of stent in a porcine coronary model. Eur Heart J 1998, 19(4):601-609.
4. Chia S., Megson I.L., Ludlam C.A., Fox K.A., Newby D.E. Preserved endothelial vasomotion and fibrinolytic function in patients with acute stent thrombosis or in-stent restenosis. Thromb Res 2003, 111(6):343-349.
5. Jenkins J.S., Webel R., Laughlin M.H., Rowland S.M., Yoklavich M.F., Branson K., et al. The effects of intravascular stents on vasomotion in porcine coronary arteries. J Invasive Cardiol 1995, 7(7):200-206.
6. Sharkawi T., Cornhill F., Lafont A., Sabaria P., Vert M. Intravascular bioresorbable polymeric stents: a potential alternative to current drug eluting metal stents. J Pharm Sci 2007, 96(11):2829-2837.
7. Ignatius A.A., Claes L.E. In vitro biocompatibility of bioresorbable polymers: poly(L, DL-lactide) and poly(L-lactide-co-glycolide). Biomaterials 1996, 17(8):831-839.
8. Jahno V.D., Ribeiro G.B., dos Santos L.A., Ligabue R., Einloft S., Ferreira M.R., et al. Chemical synthesis and in vitro biocompatibility tests of poly (L-lactic acid). J Biomed Mater Res A 2007, 83(1):209-215.
9. Smith M.J., White K.L., Smith D.C., Bowlin G.L. In vitro evaluations of innate and acquired immune responses to electrospun polydioxanone-elastin blends. Biomaterials 2009, 30(2):149-159.
10. Chen C.C., Chueh J.Y., Tseng H., Huang H.M., Lee S.Y. Preparation and characterization of biodegradable PLA polymeric blends. Biomaterials 2003, 24(7):1167-1173.
11. Middleton J.C., Tipton A.J. Synthetic biodegradable polymers as orthopedic devices. Biomaterials 2000, 21(23):2335-2346.
12. Vert M., Li S.M., Spenlehauer G., Guerin P. Bioresorbability and biocompatibility of aliphatic polyesters. J Mater Sci Mater Med 1992, 3(6):432-446.
13. Pulapura S., Kohn J. Trends in the development of bioresorbable polymers for medical applications. J Biomater Appl 1992, 6(3):216-250.
14. Bunger C.M., Grabow N., Sternberg K., Kroger C., Ketner L., Schmitz K.P., et al. Sirolimus-eluting biodegradable poly-L-lactide stent for peripheral vascular application: a preliminary study in porcine carotid arteries. J Surg Res 2007, 139(1):77-82.
15. Serruys P.W., Ormiston J.A., Onuma Y., Regar E., Gonzalo N., Garcia-Garcia H.M., et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet 2009, 373(9667):897-910.
16. Virmani R., Kolodgie F.D., Farb A., Lafont A. Drug eluting stents: are human and animal studies comparable?. Heart 2003, 89(2):133-138.
17. van der Giessen W.J., Lincoff A.M., Schwartz R.S., van Beusekom H.M., Serruys P.W., Holmes D.R., et al. Marked inflammatory sequelae to implantation of biodegradable and nonbiodegradable polymers in porcine coronary arteries. Circulation 1996, 94(7):1690-1697.
18. Lincoff A.M., Furst J.G., Ellis S.G., Tuch R.J., Topol E.J. Sustained local delivery of dexamethasone by a novel intravascular eluting stent to prevent restenosis in the porcine coronary injury model. J Am Coll Cardiol 1997, 29(4):808-816.
19. Su S.H., Chao R.Y., Landau C.L., Nelson K.D., Timmons R.B., Meidell R.S., et al. Expandable bioresorbable endovascular stent. I. Fabrication and properties. Ann Biomed Eng 2003, 31(6):667-677.
20. Uurto I., Juuti H., Parkkinen J., Kellomaki M., Keski-Nisula L., Nevalainen T., et al. Biodegradable self-expanding poly-L/D-lactic acid vascular stent: a pilot study in canine and porcine iliac arteries. J Endovasc Ther 2004, 11(6):712-718.
21. Hietala E.M., Salminen U.S., Stahls A., Valimaa T., Maasilta P., Tormala P., et al. Biodegradation of the copolymeric polylactide stent. Long-term follow-up in a rabbit aorta model. J Vasc Res 2001, 38(4):361-369.
22. Peng H.Y., Chen M., Zheng B., Wang X.G., Huo Y. Long-term effects of novel biodegradable, polymer-coated, sirolimus-eluting stents on neointimal formation in a porcine coronary model. Int Heart J 2009, 50(6):811-822.
23. Tsuji T., Tamai H., Igaki K., Kyo E., Kosuga K., Hata T., et al. Experimental and clinical studies of biodegradable polymeric stents. J Interv Cardiol 2007, 13(6):439-445.
24. Nuutinen J.P., Valimaa T., Clerc C., Tormala P. Mechanical properties and in vitro degradation of bioresorbable knitted stents. J Biomater Sci Polym Ed 2002, 13(12):1313-1323.
25. Tamai H., Igaki K., Tsuji T., Kyo E., Kosuga K., Kawashima A., et al. A biodegradable poly-l-lactic acid coronary stent in the porcine coronary artery. J Interv Cardiol 2000, 12(6):443-450.
26. Ethicon Sutures: absorbable. Coated vicryl (polygalactin 910) suture. Ethicon product catalog 2009, Ethicon Corporation.
27. Purac. Personal correspondence with manufacturer; March 8, 2010.
28. Andrade M.G., Weissman R., Reis S.R. Tissue reaction and surface morphology of absorbable sutures after in vivo exposure. J Mater Sci Mater Med 2006, 17(10):949-961.
29. Smith M.J., Smith D.C., White K.L., Bowlin G.L. Immune response testing to electrospun polymers: an important consideration in the evaluation of biomaterials. J Eng Fiber Fabr 2007, 2(2):41-48.
30. Uff C.R., Scott A.D., Pockley A.G., Phillips R.K. Influence of soluble suture factors on in vitro macrophage function. Biomaterials 1995, 16(5):355-360.
31. Boland E.D., Coleman B.D., Barnes C.P., Simpson D.G., Wnek G.E., Bowlin G.L. Electrospinning polydioxanone for biomedical applications. Acta Biomater 2005, 1(1):115-123.
32. Greisler H.P., Tattersall C.W., Klosak J.J., Cabusao E.A., Garfield J.D., Kim D.U. Partially bioresorbable vascular grafts in dogs. Surgery 1991, 110(4):645-654. discussion 654-645.
33. Endotoxin FDA 1997 Guidance Guideline on validation of the limulus amebocyte lysate test as an end-product endotoxin test for human and animal parenteral drugs, bioloigcal products, and medical devices 1997, FDA, Available from. http://www.fda.gov/downloads/BiologicsBloodVaccines/GuidanceComplianceRegulatoryInformation/Guidances/Blood/UCM080966.pdf.
34. National Research Council Guide for the Care and use of Laboratory animals 1996, National Academy Press, Washington, D.C.
35. Hedberg E.L., Kroese-Deutman H.C., Shih C.K., Crowther R.S., Carney D.H., Mikos A.G., et al. In vivo degradation of porous poly(propylene fumarate)/poly(DL-lactic-co-glycolic acid) composite scaffolds. Biomaterials 2005, 26(22):4616-4623.
36. Ethicon PDS II suture 2010, Available from. http://www.ecatalog.ethicon.com/sutures-absorbable.
37. Domb A.J., Kost J., Wiseman D.M. Handbook of biodegradable polymers 1997, Harwood Academic Publishers, Amsterdam.
38. Commandeur S., van Beusekom H.M., van der Giessen W.J. Polymers, drug release, and drug-eluting stents. J Interv Cardiol 2006, 19(6):500-506.
39. Hooper K.A., Macon N.D., Kohn J. Comparative histological evaluation of new tyrosine-derived polymers and poly (L-lactic acid) as a function of polymer degradation. J Biomed Mater Res 1998, 41(3):443-454.
40. Barrows T. Degradable implant materials: a review of synthetic absorbable polymers and their applications. Clin Mater 1986, 1(4):233-257.
41. Fischell T.A. Polymer coatings for stents. Can we judge a stent by its cover?. Circulation 1996, 94(7):1494-1495.
42. Venkatraman S., Boey F., Lao L.L. Implanted cardiovascular polymers: Natural, synthetic and bio-inspired. Prog Polym Sci 2008, 33(9):853-874.
43. Vogt F., Stein A., Rettemeier G., Krott N., Hoffmann R., vom Dahl J., et al. Long-term assessment of a novel biodegradable paclitaxel-eluting coronary polylactide stent. Eur Heart J 2004, 25(15):1330-1340.
44. De Scheerder I.K., Wilczek K.L., Verbeken E.V., Vandorpe J., Lan P.N., Schacht E., et al. Biocompatibility of biodegradable and nonbiodegradable polymer-coated stents implanted in porcine peripheral arteries. Cardiovasc Intervent Radiol 1995, 18(4):227-232.
45. Unverdorben M., Spielberger A., Schywalsky M., Labahn D., Hartwig S., Schneider M., et al. A polyhydroxybutyrate biodegradable stent: preliminary experience in the rabbit. Cardiovasc Intervent Radiol 2002, 25(2):127-132.
46. Kornowski R., Hong M.K., Tio F.O., Bramwell O., Wu H., Leon M.B. In-stent restenosis: contributions of inflammatory responses and arterial injury to neointimal hyperplasia. J Am Coll Cardiol 1998, 31(1):224-230.
47. Rapoza R. BVS Technology: understanding the principle of bioabsorbable DES 2008, ICI (Innovations in Cardiovascular Interventions), Tel Aviv.
48. Chu C.C. An in-vitro study of the effect of buffer on the degradation of poly(glycolic acid) sutures. J Biomed Mater Res 1981, 15(1):19-27.
49. Biological evaluation of medical devices - Part 6: tests for local effects after implantation 2007, 28. ISO, Geneva. 2nd ed. ISO Standards (Ed.).
50. Cha S.H., Han M.H., Choi Y.H., Yoon C.J., Baik S.K., Kim S.J., et al. Vascular responses in normal canine carotid arteries: comparison between various self-expanding stents of the same unconstrained size. Invest Radiol 2003, 38(2):95-101.
51. Kirsch E.C., Khangure M.S., Morling P., York T.J., McAuliffe W. Oversizing of self-expanding stents: influence on the development of neointimal hyperplasia of the carotid artery in a canine model. AJNR Am J Neuroradiol 2002, 23(1):121-127.
52. Lin P.H., Chronos N.A., Marijianowski M.M., Chen C., Conklin B., Bush R.L., et al. Carotid stenting using heparin-coated balloon-expandable stent reduces intimal hyperplasia in a baboon model. J Surg Res 2003, 112(1):84-90.
53. Krueger K.D., Mitra A.K., DelCore M.G., Hunter W.J., Agrawal D.K. A comparison of stent-induced stenosis in coronary and peripheral arteries. J Clin Pathol 2006, 59(6):575-579.
54. Schillinger M., Exner M., Mlekusch W., Haumer M., Ahmadi R., Rumpold H., et al. Inflammatory response to stent implantation: differences in femoropopliteal, iliac, and carotid arteries. Radiology 2002, 224(2):529-535.